Biotechnology
Angitia Biopharmaceuticals is a clinical-stage biotechnology company established in June 2018 that focuses on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. The company is currently studying two biologic product candidates in clinical trials for the treatment of osteoporosis and osteogenesis imperfecta (OI). Angitia leverages extensive team experience in bringing novel therapeutic approaches to patients with these challenging musculoskeletal conditions.
Industry
Biotechnology
Company Size
51-200 employees
Founded
2018
Remote Policy
Fully Remote
Beta · Sourced from candidate reports
Be the first to share your experience with Angitia Biopharmaceuticals.
Your reply helps other candidates know what to expect.
